First Tracks Biotherapeutics, Inc. TRAX R2K
First Tracks Biotherapeutics, Inc. operates a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases in United States. Its products includes ANB033, a novel anti-CD122 antagonist that targets the shared beta subunit of the IL-15 and IL-2 receptors; Rosnilimab, a antibody engineered to selectively deplete pathogenic T cells in both the periphery and inflamed tissues; and ANB101, a BDCA2-modulating antibody designed to specifically target plasmacytoid dendritic cells (pDCs). First Tracks Biotherapeutics, Inc. was formerly known as Biopharma Co., Inc. and changed its name to First Tracks Biotherapeutics, Inc. in February 2026. First Tracks Biotherapeutics, Inc. was founded in 2019 and is based in San Diego, California.
READ MORE ›Market & Price
Valuation
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Growth (CAGR)
PROS
No notable strengths flagged.
CONS
- Earnings shrank at -54.2% CAGR over 5 years.
- Trading 37.2% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | TRAX First Tracks Biotherapeutics, Inc. R2K | 15.96 | - | $556.88M | - | -44.64% | - | - | -54.22% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Quarterly Results
Figures in USD.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue | 0 | 0 |
| Cost of Revenue | - | - |
| Gross Profit | - | - |
| Operating Expenses | 51.28M | 52.81M |
| Operating Income | -51.28M | -52.81M |
| EBITDA | -50.67M | -52.69M |
| Interest Expense | - | - |
| Pretax Income | -47.20M | -50.48M |
| Tax Provision | - | - |
| Net Income | -47.20M | -50.48M |
| Diluted EPS | -1.36 | -1.45 |
| R&D Expense | 41.47M | 33.95M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 |
|---|---|---|
| Revenue | 0 | 0 |
| Cost of Revenue | - | - |
| Gross Profit | - | - |
| Operating Expenses | 118.46M | 181.10M |
| Operating Income | -118.46M | -181.10M |
| EBITDA | -116.08M | -178.70M |
| Interest Expense | - | - |
| Pretax Income | -106.15M | -163.71M |
| Tax Provision | - | - |
| Net Income | -106.15M | -163.71M |
| Diluted EPS | -3.05 | - |
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | - |
Compounded Profit Growth
| 5 Years: | -54.22% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | -16.00% |
| 6 Months: | - |
| 3 Months: | - |
| 1 Month: | -32.49% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 |
|---|---|---|
| Total Assets | 444.11M | 441.89M |
| Current Assets | 398.56M | 389.93M |
| Cash & Equivalents | 35.97M | 123.08M |
| Inventory | - | - |
| Receivables | - | - |
| Total Liabilities | 34.26M | 50.30M |
| Current Liabilities | 18.22M | 36.18M |
| Long Term Debt | - | - |
| Total Debt | 17.81M | 16.04M |
| Total Equity | 409.85M | 391.60M |
| Shares Outstanding | 34.75M | 34.75M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 |
|---|---|---|
| Operating Cash Flow | -93.00M | -125.81M |
| Investing Cash Flow | 144.75M | 95.40M |
| Financing Cash Flow | -87.09M | 117.52M |
| Capital Expenditure | -807.00K | -358.00K |
| Free Cash Flow | -93.81M | -126.16M |
| Net Change in Cash | -35.34M | 87.11M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2023 | Dec 2024 |
|---|---|---|
| Gross Margin % | - | - |
| Operating Margin % | - | - |
| Net Margin % | - | - |
| ROE % | -25.9% | -41.8% |
| ROCE % | -27.8% | -44.6% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 1.60% | 557.13K | $8.89M |
| 2 | iShares Trust-iShares Russell 2000 Growth ETF | 0.43% | 149.77K | $2.39M |
| 3 | Fidelity Covington Trust-Fidelity Small-Mid Multifactor ETF | 0.12% | 43.59K | $695.70K |
| 4 | Invesco Exchange-Traded Fund Trust-Invesco RAFI US 1500 Small-Mid ETF | 0.09% | 30.07K | $479.88K |
| 5 | Direxion Shares ETF Trust-Direxion Daily S&P Biotech Bull 3X ETF | 0.08% | 29.33K | $468.07K |
| 6 | -SSgA SPDR ETFS Europe I-State Street SPDR Russell 2000 US Small Cap U | 0.08% | 28.48K | $454.57K |
| 7 | Invesco Exchange-Traded Fund Trust-Invesco BuyBack Achievers ETF | 0.07% | 23.88K | $381.06K |
| 8 | Invesco Exch-Trd Self-Indexed Fd. TRT-Invesco Russell 2000 Dynamic Mul | 0.04% | 14.95K | $238.59K |
| 9 | Fidelity Commonwealth Trust-Fidelity Nasdaq Composite Index ETF | 0.02% | 8.70K | $138.80K |
| 10 | GLOBAL X FUNDS-Global X Russell 2000 ETF | 0.02% | 7.87K | $125.62K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for TRAX